Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

“…7 van Dongen et al, in a Cochrane review, conducted a subgroup analysis of patients with cancer and that 6 studies and 446 patients and resulted in an OR of 0.53 (95% CI, 0.33-0.85). 5 Although the current review included more studies and patients (11 studies and 801 cancer patients) than the 3 previous reviews, our results are consistent with theirs.…”

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

“…7 van Dongen et al, in a Cochrane review, conducted a subgroup analysis of patients with cancer and that 6 studies and 446 patients and resulted in an OR of 0.53 (95% CI, 0.33-0.85). 5 Although the current review included more studies and patients (11 studies and 801 cancer patients) than the 3 previous reviews, our results are consistent with theirs.…”

Thrombolysis and adjunct anticoagulation in patients with acute basilar artery occlusion

“…The lack of sICHs in the LMWH group supports a safer AC, whereas treatment with UFH seemed to be associated with sICH in propensity analysis. The heparin dosages and ICH rates in our cohort are in line with results from other studies and a similar LMWH regimen is used in both myocardial infarction and venous thromboembolic events with similar results, favoring LMWH with lower risk of hemorrhagic complications .…”

Major bleeding risks of different low‐molecular‐weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis

“…treatment. These results are similar to what was found in a meta-analysis [12], where all LMWHs gave lower bleeding risk as compared with unfractionated heparin (UFH) (nadroparin odds ratio [13]. In addition, another study showed that o.d.…”

“…treatment. These results are similar to what was found in a meta‐analysis , where all LMWHs gave lower bleeding risk as compared with unfractionated heparin (UFH) (nadroparin odds ratio [OR], 0.41; 95% CI, 0.14 to 1.17; tinzaparin OR, 0.30; 95% CI, 0.12 to 0.73; dalteparin OR, 0.15; 95% CI, 0.02 to 1.44), whereas enoxaparin gave risk estimates around unity (OR, 1.14; 95% CI, 0.50–2.16).…”

“…In this study, the absolute risk of major bleeding was low among patients who were registered at the anticoagulation clinic with an acute venous thrombotic event (between 2.0 to 3.5 per 1000 patients during combined treatment with VKA and LMWH), which is similar to cumulative incidences reported in clinical trials . These figures indicate that the combination of a VKA and LMWH for a short period is relatively safe for these patients.…”

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

“…7 van Dongen et al, in a Cochrane review, conducted a subgroup analysis of patients with cancer and that 6 studies and 446 patients and resulted in an OR of 0.53 (95% CI, 0.33-0.85). 5 Although the current review included more studies and patients (11 studies and 801 cancer patients) than the 3 previous reviews, our results are consistent with theirs.…”

Thrombolysis and adjunct anticoagulation in patients with acute basilar artery occlusion

“…The lack of sICHs in the LMWH group supports a safer AC, whereas treatment with UFH seemed to be associated with sICH in propensity analysis. The heparin dosages and ICH rates in our cohort are in line with results from other studies and a similar LMWH regimen is used in both myocardial infarction and venous thromboembolic events with similar results, favoring LMWH with lower risk of hemorrhagic complications .…”

Major bleeding risks of different low‐molecular‐weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis

“…treatment. These results are similar to what was found in a meta-analysis [12], where all LMWHs gave lower bleeding risk as compared with unfractionated heparin (UFH) (nadroparin odds ratio [13]. In addition, another study showed that o.d.…”

“…treatment. These results are similar to what was found in a meta‐analysis , where all LMWHs gave lower bleeding risk as compared with unfractionated heparin (UFH) (nadroparin odds ratio [OR], 0.41; 95% CI, 0.14 to 1.17; tinzaparin OR, 0.30; 95% CI, 0.12 to 0.73; dalteparin OR, 0.15; 95% CI, 0.02 to 1.44), whereas enoxaparin gave risk estimates around unity (OR, 1.14; 95% CI, 0.50–2.16).…”

“…In this study, the absolute risk of major bleeding was low among patients who were registered at the anticoagulation clinic with an acute venous thrombotic event (between 2.0 to 3.5 per 1000 patients during combined treatment with VKA and LMWH), which is similar to cumulative incidences reported in clinical trials . These figures indicate that the combination of a VKA and LMWH for a short period is relatively safe for these patients.…”

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

“…7 van Dongen et al, in a Cochrane review, conducted a subgroup analysis of patients with cancer and that 6 studies and 446 patients and resulted in an OR of 0.53 (95% CI, 0.33-0.85). 5 Although the current review included more studies and patients (11 studies and 801 cancer patients) than the 3 previous reviews, our results are consistent with theirs.…”

Thrombolysis and adjunct anticoagulation in patients with acute basilar artery occlusion

“…The lack of sICHs in the LMWH group supports a safer AC, whereas treatment with UFH seemed to be associated with sICH in propensity analysis. The heparin dosages and ICH rates in our cohort are in line with results from other studies and a similar LMWH regimen is used in both myocardial infarction and venous thromboembolic events with similar results, favoring LMWH with lower risk of hemorrhagic complications .…”

Major bleeding risks of different low‐molecular‐weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis

“…treatment. These results are similar to what was found in a meta-analysis [12], where all LMWHs gave lower bleeding risk as compared with unfractionated heparin (UFH) (nadroparin odds ratio [13]. In addition, another study showed that o.d.…”

“…treatment. These results are similar to what was found in a meta‐analysis , where all LMWHs gave lower bleeding risk as compared with unfractionated heparin (UFH) (nadroparin odds ratio [OR], 0.41; 95% CI, 0.14 to 1.17; tinzaparin OR, 0.30; 95% CI, 0.12 to 0.73; dalteparin OR, 0.15; 95% CI, 0.02 to 1.44), whereas enoxaparin gave risk estimates around unity (OR, 1.14; 95% CI, 0.50–2.16).…”

“…In this study, the absolute risk of major bleeding was low among patients who were registered at the anticoagulation clinic with an acute venous thrombotic event (between 2.0 to 3.5 per 1000 patients during combined treatment with VKA and LMWH), which is similar to cumulative incidences reported in clinical trials . These figures indicate that the combination of a VKA and LMWH for a short period is relatively safe for these patients.…”